Aurobindo Pharma Ltd has divested its step-down subsidiary, Aurobindo Pharma (Australia) Pty Ltd to Eris Pharma Australia Pty Ltd.
The Hyderabad – based Aurobindo will, however, under an agreement continue to manufacture and supply the products to Eris Pharma for Australian and New Zealand market over next few years.
“This divestment is in line with APL’s Strategy of focusing on US, EU and Key Emerging Markets,” the Bombay Stock Exchange was informed on Friday.
The subsidiary was not contributing any profit to Aurobindo, it added.
By Srinath Rao, Senior Vice President, CitiusTech A few decades back, the purpose of watches…
Pharmapack Europe: 'Basel the best location for drug device innovation in Europe thanks to combination…
New Delhi, January 07, 2025: HMP virus can travel to the brain, or it can…
~ Co-authored by Dr Sanjith Saseedharan, Director-Critical Care, S. L. Raheja Hospital- A Fortis Associate…
Patients Embrace Flexibility with 37% of Online Doctor Consultations now happening even After 6 PM,…
Launches Advanced Pathology Laboratory Offering Over 2500+ Tests in collaboration with Parashar Pathology Clinic in…